Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference
May 02 2018 - 9:33AM
Mesoblast’s proprietary allogeneic cell technology platform was
featured at the Unite to Cure Fourth International Vatican
Conference on global healthcare initiatives held in Vatican City
from April 26-28, 2018.
Sponsored by Vatican’s Pontifical Council for Culture, this
international conference is held every two years and gathers the
world’s leading scientists and physicians, patients, ethicists and
leaders of faith, government officials and philanthropists to
engage in powerful conversations about the latest scientific
breakthroughs and hope for the future.
In an address to the Conference delegates, His Holiness Pope
Francis stated that in recent years, advances in cellular research
and in the field of regenerative medicine have opened new horizons
in the areas of tissue repair and experimental therapies; a
significant chapter in scientific and human progress. For the full
speech, please see
(https://w2.vatican.va/content/francesco/en/speeches/2018/april/documents/papa-francesco_20180428_conferenza-pcc.html)
In a moderated discussion on the link between damaging
inflammation and chronic diseases, conference attendees were told
that Mesoblast’s cell technology is being evaluated as a potential
treatment for various severe and life-threatening inflammatory
conditions.
Mesoblast Chief Executive Dr Silviu Itescu explained how the
Company’s technology platform is based on mesenchymal lineage
precursor and stem cells which are believed to maintain tissue
health by sensing damaging inflammation and secreting mediators
that both modulate immune responses and promote tissue
repair.
Dr Itescu presented the latest results from trials of
Mesoblast’s Phase 3 product candidates which target severe and
life-threatening conditions where inflammation is core to the
disease process. These include trials evaluating Mesoblast
products in acute graft versus host disease, advanced and end-stage
heart failure, and chronic low back pain due to degenerative disc
disease.
Due to the serious nature of these conditions, Mesoblast is
pursuing accelerated review and approval pathways for several of
its product candidates based on receiving fast-track and
Regenerative Medicine Advanced Therapy (RMAT) designations from the
United States Food and Drug Administration (FDA).
About MesoblastMesoblast Limited (Nasdaq:MESO)
(ASX:MSB) is a global leader in developing innovative cell-based
medicines. Through a proprietary process, Mesoblast selects
highly purified mesenchymal lineage precursor and stem cells from
the bone marrow of healthy adults, and creates master cell banks
which can be industrially expanded to produce thousands of doses
from each donor that meet stringent release criteria, have lot to
lot consistency, and can be used off the shelf without the need for
tissue matching.
The Company has leveraged its proprietary technology platform to
establish a broad portfolio of late-stage product candidates.
Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates are
being evaluated in their ability to target advanced stages of
diseases with high, unmet medical needs including cardiovascular
conditions, orthopedic disorders, immunologic and inflammatory
disorders and oncologic/hematologic conditions.
Forward-Looking StatementsThis announcement
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. Forward-looking statements
include, but are not limited to, statements about the timing,
progress and results of Mesoblast’s preclinical and clinical
studies; Mesoblast’s ability to advance product candidates into,
enroll and successfully complete, clinical studies; the timing or
likelihood of regulatory filings and approvals; and the pricing and
reimbursement of Mesoblast’s product candidates, if approved. You
should read this press release together with our risk factors, in
our most recently filed reports with the SEC or on our website.
Uncertainties and risks that may cause Mesoblast’s actual results,
performance or achievements to be materially different from those
which may be expressed or implied by such statements, and
accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
For further information, please contact:
Julie
Meldrum
Schond GreenwayCorporate
Communications
Investor RelationsT: +61 3 9639
6036
T: +1 212 880
2060E: julie.meldrum@mesoblast.com
E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Sep 2023 to Sep 2024